Overview
Muller & Phipps distributes pharmaceutical and healthcare products through an island-wide network, with a newer therapeutic-nutrition offering alongside its core distribution activity. The latest filing shows a smaller loss than a year earlier, but on lower sales and with ordinary shareholders still carrying negative equity.
Price performance
The share closed at LKR 3.40 on 5 November 2026 after rising 71.4% over one month, versus a 3.0% ASPI gain. Its one-year return was 44.0% while the ASPI fell 6.9%, a sharp divergence not explained by the limited company news flow.
The reported range position is at the top of its 52-week range, while 20-day volume was 160.7% above its 60-day norm. Trading remains thin: median daily turnover was LKR 631,940, and a LKR 1 million order is more than everything that trades on a typical day (158% of it).
The three-year record contains seven falls of 15% or more, the deepest 32%, which took a year and one month to recover. That record shows that large retreats have occurred even though the share is currently at the top of its reported range.
Valuation
Conventional P/E and P/B measures are unavailable because trailing earnings and book value attributable to owners are negative. In everyday terms, there is no positive annual profit or positive net-asset base against which to measure the LKR 3.40 share price.
The market-wide valuation model places the company in the Overvalued band and scores it 1 of 100 on price against filed earnings, book value and dividends. There is no dividend on record in the last two years, so the current price provides neither an earnings multiple nor an income yield to compare with the consumer-retail sector. The company's own valuation record also cannot provide a current P/E or P/B comparison.
News and sentiment
Direct company coverage is thin, with two material articles in the past 90 days, both neutral. They reported takeover-code and Appendix 8A disclosures on 12 October 2026 relating to a share purchase, but supplied no operating or financial terms that change the earnings case.
No dividend, dated corporate action or other confirmed event is on record.
Financials
The June 2026 quarter remained loss-making despite a year-on-year improvement. Gross margin fell from 30.5% to 17.4%, operating margin improved from -16.6% to -12.8%, and net margin improved from -19.4% to -17.2%. The business still lost 17 cents for every rupee of sales, although that was 19 cents a year earlier.
Revenue fell 12.2%, while the net loss narrowed by LKR 6.2 million to LKR 22.2 million. The gross margin was the worst of the seven June quarters on record, showing that the smaller loss came despite materially weaker trading margins.
Equity attributable to owners was negative LKR 157.6 million at June 2026, across 283 million shares in issue. The LKR 5.7 million gap between operating loss and net loss shows that finance costs, tax and other non-operating items continued to deepen the loss.
Risks
The central risk is the negative equity position. Ordinary shareholders had negative equity of LKR 157.6 million at June 2026, while total debt was LKR 266.6 million; this leaves no positive owners' capital base against which debt can be assessed through a conventional gearing ratio.
Operating profit did not cover finance costs in the latest audited year, with interest cover at -2.96 times. Annual free cash flow was negative LKR 67.3 million, so the business was consuming rather than generating cash over that period.
The broader consumer-retail backdrop also became harder in October, when inflation accelerated and household living costs rose. This is sector context rather than company-specific news, but it adds pressure to a distributor whose sales already declined in the latest quarter.
Outlook
As at 5 November 2026, the next event is the September 2026 interim filing, which is due now and was expected between 2 and 14 November. It will show whether the June loss narrowing continued or whether lower sales and the weak gross margin translated into a wider loss.
The current data cannot establish a route back to positive owners' equity or sustainable profitability. It also does not provide terms for the October share-purchase disclosures, so their financial consequence cannot be assessed.